Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Dasatinib

FDA-approved product (tablet, oral), marketed as Dasatinib, Phyrago, Sprycel.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Dasatinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acute lymphoblastic leukemia
  • B-cell acute lymphoblastic leukemia
  • Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • Cancer
  • Childhood acute lymphoblastic leukemia
  • Childhood cancer
  • Chronic myelogenous leukemia
  • Lymphoblastic lymphoma
  • Lymphoid leukemia
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Bcr-abl tyrosine kinase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA54.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli50.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae24.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis49.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Dasatinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Dasatinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer

    NCT00570700 · start 2007-07

    Registered record
    Registry ID
    NCT00570700
    Conditions
    Hormone-refractory Prostate Cancer; Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Prostate Cancer; Recurrent Prostate Cancer
    Interventions
    Dasatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-07
    Completion
    2012-02
    Enrolment
    38

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHormone-refractory Prostate Cancer; Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Prostate Cancer +1 more
    InterventionDasatinib
    PhasePhase 2
    Registry statusCompleted

  • Study of Dasatinib (BMS-354825) in Patients With Solid Tumors

    NCT00339144 · start 2007-01

    Registered record
    Registry ID
    NCT00339144
    Conditions
    Tumors
    Interventions
    Dasatinib; Dasatinib; Dasatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2007-01
    Completion
    2008-09
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTumors
    InterventionDasatinib; Dasatinib; Dasatinib
    PhasePhase 1
    Registry statusCompleted

  • A Study of Dasatinib to See How Liver Impaired and Healthy Subjects Process and React to the Study Drug

    NCT00382668 · start 2006-10

    Registered record
    Registry ID
    NCT00382668
    Conditions
    Liver Diseases
    Interventions
    Dasatinib; Dasatinib; Dasatinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2006-10
    Completion
    2007-08
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Diseases
    InterventionDasatinib; Dasatinib; Dasatinib
    PhaseNot recorded
    Registry statusCompleted

  • Dasatinib in Treating Patients With Advanced Lung Cancer That Is No Longer Responding to Erlotinib or Gefitinib

    NCT00570401 · start 2006-06

    Registered record
    Registry ID
    NCT00570401
    Conditions
    Lung Cancer
    Interventions
    dasatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-06
    Completion
    2011-09
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Cancer
    Interventiondasatinib
    PhasePhase 2
    Registry statusCompleted

  • Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib

    NCT00036738 · start 2001-07-13

    Registered record
    Registry ID
    NCT00036738
    Conditions
    Adult Acute Lymphoblastic Leukemia in Remission; Adult B Acute Lymphoblastic Leukemia With t(9; 22)(q34.1; q11.2); BCR-ABL1; Blastic Phase; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood B Acute Lymphoblastic Leukemia With t(9; 22)(q34.1; q11.2); BCR-ABL1; Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Chronic Phase of Disease; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Disease
    Interventions
    Cyclosporine; Dasatinib; Fludarabine Phosphate; Imatinib Mesylate; Mycophenolate Mofetil; Nilotinib; Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation; Peripheral Blood Stem Cell Transplantation; Therapeutic Allogeneic Lymphocytes; Total-Body Irradiation
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2001-07-13
    Completion
    2018-05
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdult Acute Lymphoblastic Leukemia in Remission; Adult B Acute Lymphoblastic Leukemia With t(9; 22)(q34.1; q11.2) +12 more
    InterventionCyclosporine; Dasatinib; Fludarabine Phosphate; Imatinib Mesylate +6 more
    PhasePhase 2
    Registry statusCompleted